Describe MRSA with its mechanism of resistance, detection, treatment and control.
Mechanism of Methicillin Resistance
MRSA is Staphylococcus aureus resistant to methicillin and therefore to all beta-lactam antibiotics, through acquisition of the mecA gene.
The mecA gene, carried on a mobile element (SCCmec), encodes an altered penicillin-binding protein, PBP2a → PBP2a has very low affinity for beta-lactams → Cell wall cross-linking therefore continues even when all the normal penicillin-binding proteins are blocked → Resistance extends to every beta-lactam — penicillins, cephalosporins (except ceftaroline) and carbapenems → Because the mechanism is an altered target rather than an enzyme, beta-lactamase inhibitors such as clavulanic acid are useless
CLINICAL PEARL
The distinction between altered target and enzymatic resistance decides what will work. Ordinary penicillin resistance in staphylococci is caused by penicillinase, an enzyme — defeated by a stable penicillin such as cloxacillin. MRSA has changed the target itself, so no amount of protecting the drug helps; an entirely different class is required. Two resistance mechanisms, two completely different clinical responses.
Types and Laboratory Detection
| Type | Features |
|---|---|
| Hospital-acquired (HA-MRSA) | Affects patients with healthcare contact — surgery, devices, prolonged admission, previous antibiotics. Typically multidrug resistant beyond the beta-lactams |
| Community-acquired (CA-MRSA) | Affects previously healthy people with no healthcare contact; carries PANTON-valentine leucocidin and causes severe necrotising skin infection and necrotising pneumonia. Usually susceptible to non-beta-lactam agents such as clindamycin and co-trimoxazole |
| Livestock-associated | Related to intensive animal farming and antibiotic use in agriculture |
| Detection | Cefoxitin disc diffusion is the recommended screening method (a better inducer of mecA expression than oxacillin); chromogenic agar; and PCR for mecA or latex agglutination for PBP2a as confirmation |
| VISA and VRSA | Vancomycin-intermediate strains have thickened cell walls that trap the drug; fully vancomycin-resistant strains have acquired vanA from enterococci — still rare but of great concern |
Treatment
- Vancomycin — the standard parenteral agent; trough levels are monitored, and under-dosing causes both failure and resistance
- Teicoplanin — similar, with a longer half-life allowing once-daily and intramuscular use
- Linezolid — excellent oral bioavailability, so serious infection can be treated orally; causes reversible myelosuppression beyond two weeks, and optic and peripheral neuropathy
- Daptomycin — effective in bacteraemia and right-sided endocarditis, but inactivated BY pulmonary surfactant, so it must never be used for pneumonia; monitor creatine kinase
- Clindamycin, CO-trimoxazole, doxycycline — useful oral options in community-acquired MRSA skin infection; the D-test must be performed before using clindamycin, to exclude inducible resistance
- Ceftaroline — the only beta-lactam with MRSA activity, since it binds PBP2a; mupirocin topically for nasal decolonisation
- Combination therapy with rifampicin is used in prosthetic device infection, where rifampicin penetrates biofilm, but it must never be given alone because resistance emerges rapidly
Control and Applied Aspects
- Hand hygiene is the single most effective control measure; the hands of staff are the principal vehicle of transmission between patients
- Screening and decolonisation of carriers before elective surgery — nasal mupirocin with chlorhexidine body washes — measurably reduces surgical site infection
- Contact precautions and cohorting of colonised patients, with environmental cleaning
- Antimicrobial stewardship — particularly restricting cephalosporins and fluoroquinolones, which select strongly for MRSA
- Remove infected devices; biofilm on a line, prosthesis or valve cannot be sterilised by any antibiotic, and retention causes relapse
- MRSA rates in Indian hospitals are high, and infection control discipline matters more than the availability of any particular drug; the newer agents are expensive and their unnecessary use will produce resistance in turn
All questions in Gram-positive Cocci & Bacilli
- Q1Classify staphylococci. Describe the virulence factors, toxin-mediated diseases and laboratory diagnosis of Staphylococcus aureus. ★
- Q2Classify streptococci. Describe the virulence factors, diseases and non-suppurative sequelae of Streptococcus pyogenes. ★
- Q3Describe Corynebacterium diphtheriae with its morphology, toxin, clinical features, laboratory diagnosis and prevention. ★
- Q4Describe Clostridium tetani and Clostridium perfringens with their toxins, clinical features and management. ★
- Q5Describe Bacillus anthracis with its morphology, toxin, clinical forms and diagnosis. Add a note on other aerobic spore-bearers. ★
- SN1Describe Streptococcus pneumoniae with its identification, diseases and prevention. ★
- SN2Describe MRSA with its mechanism of resistance, detection, treatment and control. ★
- SN3Describe Clostridium botulinum and botulism with its clinical forms and management. ★
- SN4Describe Clostridioides difficile infection with its pathogenesis, diagnosis and management. ★
- SN5Describe the enterococci with their intrinsic resistance, infections and VRE. ★
- SN6Describe Listeria monocytogenes with its pathogenesis, clinical disease and treatment. ★
- SN7Compare Actinomyces and Nocardia. Add a note on mycetoma.